The tweet was deleted by the author.
But we saved everything 🙂.
Acumen Pharmaceuticals, Inc. announced the nomination of two candidates using its Enhanced Brain Delivery technology for development in the treatment of Alzheimer disease, as part of a collaboration with JCR Pharmaceuticals.
The move signals a step forward in early-stage research targeting unmet needs in neurodegenerative disorders. Additional details about the specific candidates or development timelines were not disclosed.
Acumen has previously advanced brain health research as dementia rates continue to rise. The company encouraged public engagement during Alzheimer and Brain Awareness Month. The latest candidate nominations expand on earlier efforts to address neurological conditions.